Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
Apple Restores Telegram to App Store After Content Policy Violation 
Jetstar to Charge for Overhead Cabin Bags From February 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
AUSTIN, Texas, March 20, 2018 -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced that it will present a corporate update at the 17th Annual Needham Healthcare Conference in New York on Tuesday, March 27 at 9:00 a.m. ET.
To access the live and archived webcast of the presentation, please visit the Presentations & Events section of the Aeglea BioTherapeutics investor relations website. Please connect to the website at least 15 minutes prior to the presentation to allow for any software download that may be necessary. The replay of the webcast will be available for 30 days thereafter.
About Aeglea BioTherapeutics
Aeglea is a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. The Company is developing pegzilarginase, its lead investigational therapy, for the treatment of Arginase 1 Deficiency, as monotherapy in arginine-dependent cancers and in combination with an immune checkpoint inhibitor for small cell lung cancer. In addition, Aeglea has an active research pipeline of other human enzyme-based approaches in both therapeutic areas. For more information, please visit http://aegleabio.com.
Media Contact:
David Calusdian
Sharon Merrill Associates
617.542.5300
[email protected]
Investor Contact:
Charles N. York II
Chief Financial Officer
Aeglea BioTherapeutics
[email protected]
